CN111514197A - 解酒组合物及其制备方法 - Google Patents
解酒组合物及其制备方法 Download PDFInfo
- Publication number
- CN111514197A CN111514197A CN202010078461.6A CN202010078461A CN111514197A CN 111514197 A CN111514197 A CN 111514197A CN 202010078461 A CN202010078461 A CN 202010078461A CN 111514197 A CN111514197 A CN 111514197A
- Authority
- CN
- China
- Prior art keywords
- composition according
- hangover
- hydrogen
- chemical formula
- preparing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 122
- 238000002360 preparation method Methods 0.000 title abstract description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 32
- 239000000284 extract Substances 0.000 claims abstract description 15
- 206010019133 Hangover Diseases 0.000 claims description 70
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 40
- 239000001257 hydrogen Substances 0.000 claims description 35
- 229910052739 hydrogen Inorganic materials 0.000 claims description 35
- 239000000126 substance Substances 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 24
- 150000001875 compounds Chemical class 0.000 claims description 22
- 150000002431 hydrogen Chemical class 0.000 claims description 22
- 239000000843 powder Substances 0.000 claims description 21
- 239000011787 zinc oxide Substances 0.000 claims description 20
- 244000046146 Pueraria lobata Species 0.000 claims description 18
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 244000010000 Hovenia dulcis Species 0.000 claims description 14
- 235000008584 Hovenia dulcis Nutrition 0.000 claims description 14
- 239000002537 cosmetic Substances 0.000 claims description 13
- 230000036541 health Effects 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- 235000000346 sugar Nutrition 0.000 claims description 13
- 239000011691 vitamin B1 Substances 0.000 claims description 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims description 11
- 241000304195 Salvia miltiorrhiza Species 0.000 claims description 11
- 240000008397 Ganoderma lucidum Species 0.000 claims description 10
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 10
- 230000002075 anti-alcohol Effects 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 8
- 241000219780 Pueraria Species 0.000 claims description 8
- 244000299461 Theobroma cacao Species 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 8
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 6
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims description 6
- 239000005715 Fructose Substances 0.000 claims description 6
- 229930091371 Fructose Natural products 0.000 claims description 6
- 235000019219 chocolate Nutrition 0.000 claims description 6
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 5
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 5
- 229930003451 Vitamin B1 Natural products 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 210000000582 semen Anatomy 0.000 claims description 5
- 238000000638 solvent extraction Methods 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 229960003495 thiamine Drugs 0.000 claims description 5
- 235000010374 vitamin B1 Nutrition 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 claims description 3
- 240000008917 Glycyrrhiza uralensis Species 0.000 claims description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 3
- 235000020510 functional beverage Nutrition 0.000 claims description 3
- 229930182830 galactose Natural products 0.000 claims description 3
- 235000011477 liquorice Nutrition 0.000 claims description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims 2
- 235000017443 Hedysarum boreale Nutrition 0.000 claims 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract description 10
- 239000011701 zinc Substances 0.000 abstract description 10
- 229910052725 zinc Inorganic materials 0.000 abstract description 10
- 239000003814 drug Substances 0.000 abstract description 9
- 230000035622 drinking Effects 0.000 abstract description 5
- 239000000306 component Substances 0.000 description 24
- 235000013350 formula milk Nutrition 0.000 description 23
- -1 alkyl radical Chemical class 0.000 description 19
- 239000008194 pharmaceutical composition Substances 0.000 description 12
- 235000002639 sodium chloride Nutrition 0.000 description 12
- 235000013361 beverage Nutrition 0.000 description 11
- 229930182735 Ganoderic acid Natural products 0.000 description 10
- 125000003118 aryl group Chemical group 0.000 description 10
- 238000000354 decomposition reaction Methods 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 230000002195 synergetic effect Effects 0.000 description 9
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 8
- 125000001072 heteroaryl group Chemical group 0.000 description 8
- RDMQPKIDHAFXKA-JNORPAGFSA-N Ganoderic Acid Am1 Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC(=O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CC(=O)CC(C)C(O)=O)C)CC(=O)[C@]21C RDMQPKIDHAFXKA-JNORPAGFSA-N 0.000 description 7
- 241000202807 Glycyrrhiza Species 0.000 description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
- 229930006000 Sucrose Natural products 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 235000013376 functional food Nutrition 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 208000007848 Alcoholism Diseases 0.000 description 5
- 241000628997 Flos Species 0.000 description 5
- 229930003270 Vitamin B Natural products 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 5
- 235000019156 vitamin B Nutrition 0.000 description 5
- 239000011720 vitamin B Substances 0.000 description 5
- 241000220485 Fabaceae Species 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 4
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229930183118 Tanshinone Natural products 0.000 description 4
- 201000007930 alcohol dependence Diseases 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 4
- 229940010454 licorice Drugs 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 150000004804 polysaccharides Chemical class 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- 206010006326 Breath odour Diseases 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000222336 Ganoderma Species 0.000 description 3
- 239000004378 Glycyrrhizin Substances 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 241000222341 Polyporaceae Species 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- 150000003797 alkaloid derivatives Chemical class 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 125000004104 aryloxy group Chemical group 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000005515 coenzyme Substances 0.000 description 3
- 235000007240 daidzein Nutrition 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 3
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 3
- 229960004949 glycyrrhizic acid Drugs 0.000 description 3
- 235000019410 glycyrrhizin Nutrition 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 150000002989 phenols Chemical class 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 3
- 239000011678 thiamine pyrophosphate Substances 0.000 description 3
- 235000010487 tragacanth Nutrition 0.000 description 3
- 239000000196 tragacanth Substances 0.000 description 3
- 229940116362 tragacanth Drugs 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- HARGZZNYNSYSGJ-UHFFFAOYSA-N 1,2 dihydrotanshinquinone Natural products C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)CO1 HARGZZNYNSYSGJ-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- HARGZZNYNSYSGJ-JTQLQIEISA-N Dihydrotanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2[C@@H](C)CO1 HARGZZNYNSYSGJ-JTQLQIEISA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- HJBUYKZTEBZNSH-ZRWXNEIDSA-N Neoliquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C(=O)C[C@H](O2)C=3C=CC(O)=CC=3)C2=C1 HJBUYKZTEBZNSH-ZRWXNEIDSA-N 0.000 description 2
- HJBUYKZTEBZNSH-ONJCETCRSA-N Neoliquiritin Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C(=O)C[C@@H](O2)C=3C=CC(O)=CC=3)C2=C1 HJBUYKZTEBZNSH-ONJCETCRSA-N 0.000 description 2
- 206010029216 Nervousness Diseases 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 240000003152 Rhus chinensis Species 0.000 description 2
- 235000014220 Rhus chinensis Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000005332 alkyl sulfoxy group Chemical group 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 125000005110 aryl thio group Chemical group 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- KXNYCALHDXGJSF-UHFFFAOYSA-N dihydroisotanshinone I Natural products CC1=CC=CC2=C(C(C=3OCC(C=3C3=O)C)=O)C3=CC=C21 KXNYCALHDXGJSF-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 229960003720 enoxolone Drugs 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 229930184104 ganoderiol Natural products 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
- 235000008696 isoflavones Nutrition 0.000 description 2
- JBQATDIMBVLPRB-UHFFFAOYSA-N isoliquiritigenin Natural products OC1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 JBQATDIMBVLPRB-UHFFFAOYSA-N 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- GSZUGBAEBARHAW-UHFFFAOYSA-N sophoraflavone B Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=CC=C3C(=O)C=2)C=C1 GSZUGBAEBARHAW-UHFFFAOYSA-N 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 235000008170 thiamine pyrophosphate Nutrition 0.000 description 2
- IWLROWZYZPNOFC-UHFFFAOYSA-O thiamine triphosphate Chemical compound CC1=C(CCOP(O)(=O)OP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N IWLROWZYZPNOFC-UHFFFAOYSA-O 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 150000003648 triterpenes Chemical group 0.000 description 2
- 239000008371 vanilla flavor Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- PKEGICXVZMKJPR-UHFFFAOYSA-N (-)-neocryptotanshinone Natural products C1CCC(C)(C)C2=CC=C(C(C(C(CO)C)=C(O)C3=O)=O)C3=C21 PKEGICXVZMKJPR-UHFFFAOYSA-N 0.000 description 1
- UZRUFOMXLWRIQS-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)-2-hydroxypropanamide Chemical compound [C@H](CC1=CC=C(O)C(O)=C1)(O)C(=O)N UZRUFOMXLWRIQS-MRVPVSSYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- LGZFJHSOBYVDLA-JTQLQIEISA-N 1-hydroxy-2-[(2r)-1-hydroxypropan-2-yl]-8,8-dimethyl-6,7-dihydro-5h-phenanthrene-3,4-dione Chemical compound C1CCC(C)(C)C=2C1=C1C(=O)C(=O)C([C@H](CO)C)=C(O)C1=CC=2 LGZFJHSOBYVDLA-JTQLQIEISA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- MTBPONUDAZRCLE-UHFFFAOYSA-N 2-hydroxy-3-methylbenzoic acid;methyl 2-hydroxybenzoate Chemical compound COC(=O)C1=CC=CC=C1O.CC1=CC=CC(C(O)=O)=C1O MTBPONUDAZRCLE-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- KSDSYIXRWHRPMN-UHFFFAOYSA-N 4'-O-beta-D-Galactopyranoside-6''-p-Coumaroylprunin-4',5,7-Trihydroxyflavanone Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC(O)=C3C(=O)C2)C=C1 KSDSYIXRWHRPMN-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N Adenosine Natural products C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 description 1
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 206010048909 Boredom Diseases 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- DLAVDLMEXLDBEF-UHFFFAOYSA-N C(CC)C=1C(=C(C(=O)O)C=CC1)O.OC1=C(C(=O)OCCC)C=CC=C1 Chemical compound C(CC)C=1C(=C(C(=O)O)C=CC1)O.OC1=C(C(=O)OCCC)C=CC=C1 DLAVDLMEXLDBEF-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- NJZMSAAKSXZIEC-UQOIKQOMSA-N Ganoderic acid beta Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1C[C@H](O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CC\C=C(/C)C(O)=O)C)CC(=O)[C@]21C NJZMSAAKSXZIEC-UQOIKQOMSA-N 0.000 description 1
- NJZMSAAKSXZIEC-UHFFFAOYSA-N Ganoderic acid beta Natural products CC(CCC=C(/C)C(=O)O)C1CC(=O)C2(C)C3=C(C(=O)CC12C)C4(C)CCC(O)C(C)(C)C4CC3O NJZMSAAKSXZIEC-UHFFFAOYSA-N 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 241000131390 Glis Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 235000003935 Hippophae Nutrition 0.000 description 1
- 241000229143 Hippophae Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022653 Intestinal haemorrhages Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 208000006264 Korsakoff syndrome Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- FURUXTVZLHCCNA-UHFFFAOYSA-N Liquiritigenin Natural products C1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-UHFFFAOYSA-N 0.000 description 1
- DEMKZLAVQYISIA-ONJCETCRSA-N Liquiritin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc([C@@H]2Oc3c(C(=O)C2)ccc(O)c3)cc1 DEMKZLAVQYISIA-ONJCETCRSA-N 0.000 description 1
- DEMKZLAVQYISIA-UHFFFAOYSA-N Liquirtin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical class [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- ZDZOJQPZBICBMD-UHFFFAOYSA-N Oleoyl neocryptotanshinone Natural products CCCCCCCCC=C/CCCCCCCC(=O)OCC(C)C1=C(O)C(=O)c2c3CCCC(C)(C)c3ccc2C1=O ZDZOJQPZBICBMD-UHFFFAOYSA-N 0.000 description 1
- 206010061323 Optic neuropathy Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 229930194268 Salvianic acid Natural products 0.000 description 1
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 208000005428 Thiamine Deficiency Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 description 1
- 235000010081 allicin Nutrition 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 125000005264 aryl amine group Chemical group 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- QNDQILQPPKQROV-UHFFFAOYSA-N dizinc Chemical compound [Zn]=[Zn] QNDQILQPPKQROV-UHFFFAOYSA-N 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 229940015042 glycopyrrolate Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 125000005241 heteroarylamino group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000005462 imide group Chemical group 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004388 isoflavanoid group Chemical group 0.000 description 1
- DXDRHHKMWQZJHT-FPYGCLRLSA-N isoliquiritigenin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1O DXDRHHKMWQZJHT-FPYGCLRLSA-N 0.000 description 1
- 235000008718 isoliquiritigenin Nutrition 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- FURUXTVZLHCCNA-AWEZNQCLSA-N liquiritigenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-AWEZNQCLSA-N 0.000 description 1
- DEMKZLAVQYISIA-ZRWXNEIDSA-N liquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C([C@H]2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-ZRWXNEIDSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- ZFUPIYVNSQCGMC-UHFFFAOYSA-L methylaluminum(2+) dihydroxide Chemical compound [OH-].C[Al+2].[OH-] ZFUPIYVNSQCGMC-UHFFFAOYSA-L 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 125000002560 nitrile group Chemical group 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZDZOJQPZBICBMD-SEYXRHQNSA-N oleoyl neocryptotanshinone Chemical compound C1CCC(C)(C)C2=CC=C(C(C(C(C)COC(=O)CCCCCCC\C=C/CCCCCCCC)=C(O)C3=O)=O)C3=C21 ZDZOJQPZBICBMD-SEYXRHQNSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002898 organic sulfur compounds Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- MPQXHAGKBWFSNV-UHFFFAOYSA-N oxidophosphanium Chemical group [PH3]=O MPQXHAGKBWFSNV-UHFFFAOYSA-N 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000004108 pentose phosphate pathway Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-N phosphine group Chemical group P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G1/00—Cocoa; Cocoa products, e.g. chocolate; Substitutes therefor
- A23G1/30—Cocoa products, e.g. chocolate; Substitutes therefor
- A23G1/32—Cocoa products, e.g. chocolate; Substitutes therefor characterised by the composition containing organic or inorganic compounds
- A23G1/36—Cocoa products, e.g. chocolate; Substitutes therefor characterised by the composition containing organic or inorganic compounds characterised by the fats used
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G1/00—Cocoa; Cocoa products, e.g. chocolate; Substitutes therefor
- A23G1/30—Cocoa products, e.g. chocolate; Substitutes therefor
- A23G1/32—Cocoa products, e.g. chocolate; Substitutes therefor characterised by the composition containing organic or inorganic compounds
- A23G1/40—Cocoa products, e.g. chocolate; Substitutes therefor characterised by the composition containing organic or inorganic compounds characterised by the carbohydrates used, e.g. polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G1/00—Cocoa; Cocoa products, e.g. chocolate; Substitutes therefor
- A23G1/30—Cocoa products, e.g. chocolate; Substitutes therefor
- A23G1/32—Cocoa products, e.g. chocolate; Substitutes therefor characterised by the composition containing organic or inorganic compounds
- A23G1/48—Cocoa products, e.g. chocolate; Substitutes therefor characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/60—Sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/68—Acidifying substances
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种解酒组合物,更为详细地涉及一种含有锌及中药物质萃取物的解酒组合物及其制备方法。本发明的解酒组合物具有在饮用或摄取后两个小时以内分解大部分酒精的效果,这与以往的解酒产品相比具有明显卓越的效能。
Description
技术领域
本发明涉及一种解酒组合物,更为详细地涉及一种含有锌及中药物质萃取物的解酒组合物及其制备方法。
背景技术
自1980年代以来,由于社会动荡和经济不稳定,国内白酒的销售量增长,1996年每个成年人的平均每日酒精消费量为六瓶啤酒。就国民健康而言,这是一个令人担忧的问题,并且由于饮酒文化中的频繁酗酒,人们很关注解酒药物或饮料。
当酒中所含的大量酒精成分进入人体时,由于代谢系统平衡的破坏,难以维持体内平衡。尤其是,对于受影响最严重的肝脏来说,长期饮酒会发生脂肪肝和肝硬化等功能障碍,短期会因宿醉(hangover)如口渴、精神无聊、疲劳、记忆力减退、消化不良、呕吐、腹泻和维生素缺乏症受苦。由此,不仅正常的日常活动很困难,而且无力的活动也会引起严重影响本人及他人的副作用。
为了减轻如上所述的宿醉,已经开发及出售各种剂型的解酒产品。作为一例,韩国公开专利公报第2001-0019767号公开一种用于解酒的天然茶及其制备方法,其中公开使用葛花、葛根、甘草、白术、陈皮、泽泻、枸杞和生姜。韩国专利公报第1534550号公开一种包括黄漆木的解酒剂及其制备方法,并且公开了将黄漆木有效成分含量增加的粉末溶解在水、酒或液体饮料中以用作饮料。
如此,为了解酒开发出采用各种方法的产品并进行了销售,但是即使是少量也具有明显卓越的解酒效果的产品的开发尚无多少进展。
(专利文献1)韩国公开专利公报第2001-0019767号
(专利文献2)韩国专利公报第1534550号
发明内容
本发明的目的是提供一种解酒组合物的制备方法,该方法按规定的比例混合枳椇子、葛根、葛花、甘草、丹参、灵芝萃取物和锌及维生素B1,以制备解酒效果显著提高的解酒组合物,本发明的目的是还以容易服用的形式提供由所述方法制备的解酒组合物。
本发明的解酒组合物的制备方法包括:溶剂萃取包含枳椇子、葛根、葛花及甘草的第一混合物以获得萃取物的步骤:及溶解所述萃取物的干粉、氧化锌(zinc oxide)及具有下列化学式1或化学式2的结构的糖化合物、其衍生物或其盐的第二混合物,以获得锌-糖复合物溶液。
[化学式1]
[化学式2]
所述R1至R5及R7至R10分别独立地为氢或(C1-C7)烷基;
所述R6为氢、羟基、羟基(C1-C7)烷基或(C1-C7)烷氧基。
在本发明的一例的解酒组合物的制备方法中,所述第一混合物相对于所述枳椇子100重量份,可包含1~50重量份的葛根、1~50重量份的葛花及1~10重量份的甘草。
在本发明的一例的解酒组合物的制备方法中,所述溶剂萃取时的溶剂可为水或碳原子数为(C1-C4)的低元醇。
在本发明的一例的解酒组合物的制备方法中,在所述溶剂萃取时,可在70~200℃中萃取1~20小时。
在本发明的一例的解酒组合物的制备方法中,所述第二混合物相对于所述干粉1重量份,可包含100~500重量份的氧化锌及10~100重量份的所述糖化合物。
在本发明的一例的解酒组合物的制备方法中,所述R1至R5及R7至R10可分别独立地为氢或(C1-C3)烷基;所述R6可为氢、羟基、羟基(C1-C3)烷基或(C1-C3)烷氧基。
在本发明的一例的解酒组合物的制备方法中,所述R1至R5及R7至R10可为氢,所述R6可为氢、羟基或-(CH)2-OH。
在本发明的一例的解酒组合物的制备方法中,具有所述化学式1或化学式2的结构的化合物可为葡萄糖、果糖或半乳糖。
在本发明的一例的解酒组合物的制备方法中,所述第一混合物可进一步包括丹参、灵芝或其混合物。
在本发明的一例的解酒组合物的制备方法中,所述第二混合物可进一步包括维生素B1。
在本发明的一例的解酒组合物的制备方法中,所述第二混合物及维生素B1可在分别灭菌后混合。
此外,本发明的解酒组合物的有效成分可含有:具有下列化学式1或化学式2的结构的糖化合物、其衍生物或其盐;氧化锌(zinc oxide);及枳椇子、葛根、葛花及甘草的混合萃取物。
[化学式1]
[化学式2]
所述R1至R5及R7至R10分别独立地为氢或(C1-C7)烷基;
所述R6为氢、羟基、羟基(C1-C7)烷基或(C1-C7)烷氧基。
在本发明的一例的解酒组合物中,所述R1至R5及R7至R10可分别独立地为氢或(C1-C3)烷基;所述R6可为氢、羟基、羟基(C1-C3)烷基或(C1-C3)烷氧基。
在本发明的一例的解酒组合物中,所述R1至R5及R7至R10可为氢,所述R6可为氢、羟基或-(CH)2-OH。
此外,本发明的健康功能饮料含有所述解酒组合物。
此外,本发明的健康功能巧克力含有所述解酒组合物。
此外,本发明的药品或药学组合物含有所述解酒组合物。
本发明的化妆品含有所述解酒组合物。
本发明的解酒组合物具有在饮用或摄取后两个小时以内分解大部分酒精的效果,这与以往的解酒产品相比具有明显卓越的效能。
附图说明
图1为不同时间的呼气酒精浓度结果。
图2为相对于初始浓度的呼气中酒精残留率的结果。
图3为解酒组合物所带来的恢复率(%)及达到0%的人员的分率的结果。
具体实施方式
下面,参照所附的表格或附图详细说明本发明的解酒组合物及其制备方法。
当有附图时,这仅作为示例提供,以保证能够向本领域技术人员充分传递本发明的思想。因此,本发明不限于所提出的附图,而是可以以其他形式具体化,所述附图可以被放大显示以阐明本发明的思想。
此时,除非有其他定义,所使用的技术术语和科学术语具有本发明所属技术领域的技术人员普遍理解的含义,在以下描述和附图中,省略了可能导致本发明要点不清楚的公知功能及结构的说明。
另外,除非在上下文中特别指出,否则在本发明的说明书中使用的单数形式也可以意图包括复数形式。
另外,在本发明的说明书中,在没有特别说明的情况下使用的单位以重量为准,作为一例,%或比例的单位是指重量%或重量比。
另外,在本发明的说明书中,“包括”这一表述是具有与“具备”、“含有”、“具有”或“特征在于……”等表述等效的含义的开放式记载,其不排除未进一步列出的要素、材料或工序。另外,“实质上由……构成”这一表述意味着未与特定的元素、材料或工序一起列出的其他元素、材料或工序可以以不对本发明的至少一个基本和新颖的技术思想产生不能接受的显著影响的程度存在。此外,“由……组成”这一表述意味着仅存在所描述的要素、材料或工序。
在本发明的说明书中使用的术语“组分”、“组合物”、“化合物的组合物”、“化合物”、“药物”、“药学活性剂”、“活性剂”、“治愈”、“治疗法”、“治疗”或“药剂”为了表示向给药对象(人或动物)时通过局部及/或全身作用引起所需药学及/或生理作用的化合物或多个化合物或物质的组合物,它们可以互换使用。
在本发明的说明书中使用的术语“治疗”或“治疗法”(还有其不同的形式)包括预防(例如,预防治疗)、治愈或减轻性治疗。在本申请中使用的术语“进行治疗的”包括用于减轻或减少状态、疾病或障碍中至少一种的不利或负面作用或症状。
在本发明中,“样品”或“试样”表示用于分析的对象,在整个说明书中用作相同的含义。
在本说明书中,术语“取代的或未取代的”表示的是由选自氘;卤基;氰基;腈基;硝基;羟基;羰基;酯基;酰亚胺基;氨基;氧化膦基;烷氧基;芳氧基;烷基硫氧基;芳硫基(Arylthioxy group);烷基硫氧基;芳硫氧基;甲硅烷基;硼基;烷基;环烷基;烯基;芳基;芳烷基;芳烯基;烷基芳基;烷基胺基;芳烷基胺基;杂芳基胺基;芳胺基;芳基膦基;或包括N、O和S原子中的一个以上原子的杂芳基构成的组中的一种以上取代基取代或未取代,或者上述例示的取代基中的两个以上取代基连接的取代或未取代的情况。例如,“两个以上的取代基连接的取代基”可以是联苯基。即,联苯基可以是芳基,也可以解释为两个苯基连接的取代基。
在本说明书中记载的术语“烷基”是指仅由碳和氢原子组成的一价直链或支链的饱和烃自由基,这种烷基自由基的示例包括但不限于甲基、乙基、丙基、异丙基、丁基、异丁基、叔丁基、戊基和己基等。
在本说明书中记载的术语“烷氧基”是指氧和烷基键合的一价-O-烷基自由基,其中“烷基”如上所定义。这种烷氧基原子团的示例包括但不限于甲氧基、乙氧基、异丙氧基、丁氧基、异丁氧基和叔丁氧基等。
在本说明书中记载的术语“芳基”是指从芳族烃去除一个氢而衍生的有机自由基,其包括在各环中适当地含有四到七个环原子,优选含五或六个环原子的单环系或稠合环系,还包括多个芳基通过单键连接的形式。具体示例包括但不限于苯基、萘基、联苯基和茚基(indenyl)等。
在本说明书中记载的术语“杂芳基”是指包含一到四个选自N、O和S中的杂原子作为芳族环骨架原子并且其余的芳族环骨架原子为碳的芳族基团。它是五到六元单环杂芳基及与一个以上的苯环稠合的多环杂芳基,可以部分饱和。另外,本发明中的杂芳基还包括一个以上的杂芳基通过单键连接的形式。所述杂芳基的示例包括但不限于吡咯、吲哚、喹啉、异喹啉、吡啶、嘧啶、恶唑、噻唑、噻二唑、三唑、咪唑、苯并咪唑、异恶唑、苯并异恶唑、噻吩、苯并噻吩、呋喃和苯并呋喃等。所述杂芳基可以在环中具有碳原子或氮原子作为结合位点。
在本说明书中记载的术语“芳烷基”是指取代有具有一、二或三个环的芳族碳环的烷基,例如包括但不限于苄基等。
在本说明书中记载的术语“芳氧基”是指氧和芳基键合的单价自由基,其中“芳基”如上所定义。这种芳氧基自由基的示例包括但不限于苯氧基和萘氧基等。
在本说明书中记载的术语“芳基烷氧基”是指芳烷基的烷基和氧键合的单价自由基,其中“芳烷基”如上所定义。这种芳基烷氧基自由基的示例包括但不限于苄氧基等。
下面,详细说明本发明的解酒组合物的制备方法。
本发明的解酒组合物的制备方法包括:溶剂萃取包含枳椇子、葛根、葛花及甘草的第一混合物以获得萃取物的步骤;及溶解所述萃取物的干粉、氧化锌(zinc oxide)及具有下列化学式1或化学式2的结构的糖化合物、其衍生物或其盐的第二混合物,以获得锌-糖复合物溶液的步骤。
[化学式1]
[化学式2]
所述R1至R5及R7至R10分别独立地为氢或(C1-C7)烷基;
所述R6为氢、羟基、羟基(C1-C7)烷基或(C1-C7)烷氧基。
枳椇子(Hoveniae Semen Cum Fructus)是属于沙棘科的落叶乔木,在韩国的忠清北道、庆尚北道等的海拔400m以下的地区生长,已知也分布在日本和中国大陆。其果柄中含有蔗糖、葡萄糖、果糖、过氧化氢酶和过氧化物酶。总糖含量占全部的约13重量%,葡萄糖和蔗糖的含量大致相同。
葛根(Puerariae Radix)表示属于豆科的葛藤的去除周皮后的根部分,所述根中含有异黄酮化合物黄豆苷元(4’-7-二羟基异黄酮)C15H10O4、黄豆苷(黄豆苷元-7-糖苷)C2H20O9、葛根素(8-C-葡萄吡喃糖黄豆苷元;8-C-glucopyranosyl daidzein)C21H20O9、葛根素木糖苷(Puerarin xyloside)、木犀草素生物素A C16H12O5(融点214~216℃)等和淀粉(10~14重量%)及香豆素等。
葛花(Puerariae Flos)表示属于豆科的葛藤的花朵部分,用于解渴、缓解宿醉引起的呕吐、缓解食欲不振或改善肠出血等。
甘草(Glycyrrhiza uralensis Fisxher)为属于豆科(Leguminosae)的植物,以属于三萜(triterpenoid)系统sponines的甘草甜素(glycyrrhizin)和甘草次酸(glycyrrhetinic acid)为主,含有属于类黄酮(flavonoids)的甘草素(liquiritigenin)、异甘草素(isoliquiritigenin)、甘草甙(liquiritin),新甘草甙(neoliquiritin)等、属于异黄酮(isoflavonoid)系统的甘油雌酮(glycestrone)、甘草酚(glycyrol)、异甘草酚(isoglycyrol)、大蒜素(licoridin)、7-乙酰氧基-2-甲基异黄酮(7-acetoxy-2-methylisoflavone)等,其具有抗炎、抗溃疡作用、消炎作用(antiphlogistic effect)、解热作用(antipyretic effect)及止痛作用(analgestic effect),并在雌激素激活(estrogenactivation)等中使用。
丹参(Salviae Miltiorrhizea Radix)指的是唇形科的根,其主要成分含有属于双萜类(diterpenoid)的丹参酮(tanshinone)I、II、IIA、IV、油酰新隐丹参酮(oleoylneocryptotanshinone)、油酰丹参新醌(oleoyl danshenxinkun)、新隐丹参酮(neocryptotanshinone)、二氢丹参酮(dihydrotanshinone)I、丹参新醌(danshenxinkun)A、B、新隐丹参酮(neocryptotanshinone)II、6,12-二羟基阿松香-5,8,11,13-四烯-7-酮(6,12-dihydroxyabieta-5,8,11,13-teraen-7-one)等,并且含有属于酚类化合物(Phenolic compound)的迷迭香酸(rosmarinic acid)、紫精酸(lithospermic acid)A、B、丹酚酸(salvianolic acid)A、B等,并且含有属于生物碱(Alkaloid)的丹参酮(salviamiltamide)、3-(3',4'-二羟基苯基)-(2R)-内酰胺(3-(3',4'-dihydroxyphenyl)-(2R)-lactamide)等。已知丹参具有有利于血管舒张、心脏病的改善及治疗、肝细胞保护、脑细胞保护及抗癌等的作用。
灵芝(Ganoderma lucidum Leyss.ex Fr.Karsten)为多孔菌科(Polyporaceae)及其同属近似种的子实体,其主要成分为三萜(triterpene),含有灵芝酸(ganoderic acid)A~T、灵芝酸β、灵芝醇(ganoderiol)F、灵芝酮二醇(ganodermanondiol)、赤芝酸(lucidenicacid)A~P、赤芝醛(lucialdehyde)A~S、赤芝酸甲酯(methyl lucidenate)F、腺苷内酯(lucidenolactone)、灵芝酸甲酯(methyl ganoderate)E、F、赤芝酸甲酯(methyllucidenate)P、Q、L、26-羟基-5α-羊毛甾-7,9(11)(26-hydroxy-5α-lanosta-7,9(11))、24-三烯-3,22-二酮(24-triene-3,22-dione)等,并且含有属于多糖(Polysaccharide)的GL-1、灵芝多糖(ganoderan)B、C等、属于蛋白聚糖(Proteoglycan)的GLIS等。已知灵芝具有抗肿瘤、降低血中LDL胆固醇数值以及抑制灵芝酸衍生物的胆固醇合成的作用。已知多糖类成分还具有保护肝组织不受损伤、抑制肝纤维化的作用。
锌(Zinc)为原子序数30的元素,其为在人体内构成细胞且控制生理功能的一种典型的无机物。锌为构成与细胞的新陈代谢相关的300个以上酶的重要成分(Cherasse Y,Urade Y(2017).International Journal of Molecular Sciences.18(11):2334)。锌负责调节胰岛素合成及分泌量、预防糖尿病、促进细胞合成的重要作用,从而促进成长。锌用于增加免疫力,干预T淋巴细胞、巨噬细胞和白细胞等各种免疫细胞的生成及活性,在腹泻、如粉刺及湿疹的皮肤病等中使用。缺锌时,可能会引发慢性肝病、慢性肾病、镰状细胞病、糖尿病、恶性肿瘤及其他慢性病(Prasad.A.S.(2003).British Medical Journal.326(7386):409-10)。食品药品监督部门建议的一天锌摄取量为10-20mg,WHO规定的男性摄取量为30-60mg,女性摄取量为30-45mg。
维生素B1(硫胺素,thiamin)为水溶性维生素,其为具有化学式C12H17N4OS的无色有机硫化合物,在位于中央的碳上通过亚甲基桥(methylene bridge)连接有含氮的六边形环(pyrimidine)及含硫的五边形环(thiazole)。在大部分组织中,80%的维生素B1转化为辅酶形式的焦磷酸硫胺(thiamin pyrophosphate,TPP)并作为辅酶发挥作用,并且参与以碳水化合物代谢为主的能量代谢。在脑等神经组织中,维生素B1转化为三磷酸硫胺(thiamintriphosphate,TTP)。所述TPP作为干预在DNA和RNA的合成中需要的磷酸戊糖途径的酶的辅酶发挥作用,从而干预核酸的合成。
由于所有细胞需要能量,若缺乏人体必要营养素维生素B1,会影响身体的所有器官,因维生素B1的缺乏引发的疾病已知有角化病、韦尼克-科尔萨科夫综合征、视神经病变和射线病等(McCandless,David(2010).Thiamine Deficiency and Associate ClinicalDisorders.New York,NY:Humana Press.pp.157-159)。
根据本发明的一实施例的结果,与分别使用所述中药物质的萃取物或锌成分等的情况相比,按照本发明制备方法的比例混合所述成分制备混合后评价解酒效果时,确认到在明显加快的时间内表现出酒精成分的分解效果。发明人认为这是因为按照本发明制备方法混合所述中药物质的萃取物及锌成分等来制备时,虽然不明其原因,在酒精成分的分解上发生了相乘效果。
本发明的所述糖化合物的可接受的盐优选可以列举由无机酸形成的加成盐,例如盐酸盐、硫酸盐、磷酸盐、氢溴酸盐、氢碘酸盐硝酸盐、焦硫酸盐、偏磷酸盐等;由有机酸形成的加成盐,例如柠檬酸盐、草酸盐、苯甲酸盐、乙酸盐、三氟乙酸盐、丙酸盐、琥珀酸盐、富马酸盐、乳酸盐、马来酸盐、酒石酸盐、戊二酸盐、甲磺酸盐、甲苯磺酸盐、磺酸盐等;或者金属盐,例如锂盐、钠盐、钾盐、镁盐、钙盐等,但不限于此。
在本发明的一例的解酒组合物的制备方法中,所述第一混合物相对于所述枳椇子100重量份,包括1~50重量份的葛根、1~50重量份的葛花及1~10重量份的甘草,优选相对于所述枳椇子100重量份,包括5~40重量份的葛根、5~40重量份的葛花及1~8重量份的甘草,更加优选相对于枳椇子100重量份,包括10~35重量份的葛根、10~35重量份的葛花及1~6重量份的甘草,但本发明的范围不限于此。在所述范围内,能够获得本发明解酒组合物的酒精分解速度显著提高的相乘效果,因此优选。
在本发明的一例的解酒组合物的制备方法中,所述溶剂萃取时的溶剂可为水或碳原子数为(C1-C4)的低元醇,优选可以使用水,但并不限于此。当使用水或纯净水时,萃取时各种中药成分有效成分的损失小,而且组合物中不会含有附加的酒精成分,因此优选。
在本发明的一例的解酒组合物的制备方法中,在所述溶剂萃取时,在一个示例中,萃取温度及时间分别可为70~200℃及1~20小时,优选可为80~170℃及2~15小时,更优选可为90~140℃及3~10小时,但并不限于此。在所述范围内,本发明的解酒组合物中所含的有效成分的含量增加,因此优选。
在本发明的一例的解酒组合物的制备方法中,所述第二混合物相对于所述干粉1重量份,可包含100~500重量份的氧化锌及10~100重量份的所述糖化合物,优选相对于所述干粉1重量份,可包含150~450重量份的氧化锌及20~85重量份的所述糖化合物,更加优选相对于所述干粉1重量份,可包含200~400重量份的氧化锌及30~70重量份的所述糖化合物,但并不限于此。在所述范围内,能够获得本发明解酒组合物的酒精分解速度显著提高的相乘效果,因此优选。
在本发明的一例的解酒组合物的制备方法中,所述R1至R5及R7至R10可分别独立地为氢或(C1-C3)烷基;所述R6可为氢、羟基、羟基(C1-C3)烷基或(C1-C3)烷氧基。在所述范围内,能够获得本发明解酒组合物的酒精分解速度显著提高的相乘效果,因此优选。
在本发明的一例的解酒组合物的制备方法中,所述R1至R5及R7至R10可为氢,所述R6可为氢、羟基或-(CH)2-OH。在所述范围内,能够获得本发明解酒组合物的酒精分解速度显著提高的相乘效果,因此优选。
在本发明的一例的解酒组合物的制备方法中,具有所述化学式1或化学式2的结构的化合物可为葡萄糖、果糖或半乳糖,所述化合物的一例可为如下的化学式的形式,但并不限于此。
在所述范围内,能够获得本发明解酒组合物的酒精分解速度显著提高的相乘效果,因此优选。
在本发明的一例的解酒组合物的制备方法中,所述第一混合物可进一步包括丹参、灵芝或其混合物。
对所述丹参或灵芝来说,相对于所述枳椇子100重量份,可进一步包括1~50重量份的丹参及1~10重量份的灵芝,优选相对于所述枳椇子100重量份,可包括5~40重量份的丹参及1~8重量份的灵芝,更加优选相对于枳椇子100重量份,可包括10~30重量份的丹参及1~6重量份的灵芝,但本发明的范围并不限于此。在所述范围内,能够获得本发明解酒组合物的酒精分解速度显著提高的相乘效果,因此优选。
在本发明的一例的解酒组合物的制备方法中,所述第二混合物可进一步包括维生素B1。
相对于所述干粉1重量份,可进一步包括1~100重量份的所述维生素B1,优选可包括10~80重量份的所述维生素B1,更加优选可包括20~60重量份的所述维生素B1,本发明的范围并不限于此。在所述范围内,能够获得本发明解酒组合物的酒精分解速度显著提高的相乘效果,因此优选。
在本发明的一例的解酒组合物的制备方法中,所述第二混合物及维生素B1可在分别灭菌后混合。
在一个示例中,所述灭菌可在70~150℃中执行0.1~10分钟,优选可在75~130℃中执行0.1~5分钟,更优选可在80~100℃中执行0.1~2分钟,但本发明的范围并不限于此,在所述范围内,能够最大限度地减少第二混合物及维生素B1成分的变形或损失,能够获得本发明解酒组合物的酒精分解速度显著提高的相乘效果,因此优选。
下面对本发明的解酒组合物进行详细说明。
本发明的解酒组合物的有效成分含有:具有下列化学式1或化学式2的结构的糖化合物、其衍生物或其盐;氧化锌(zinc oxide);及枳椇子、甘草、葛花及葛根的混合萃取物。
[化学式1]
[化学式2]
所述R1至R5及R7至R10分别独立地为氢或(C1-C7)烷基;
所述R6为氢、羟基、羟基(C1-C7)烷基或(C1-C7)烷氧基。
在本发明的一例的解酒组合物中,所述R1至R5及R7至R10可分别独立地为氢或(C1-C3)烷基;所述R6可为氢、羟基、羟基(C1-C3)烷基或(C1-C3)烷氧基。
在本发明的一例的解酒组合物中,所述R1至R5及R7至R10可为氢,所述R6可为氢、羟基或-(CH)2-OH。
本发明的所述R1和R6以及R7和R11可根据情况彼此相连而形成环,但并不限于此。
下面,对使用本发明解酒组合物的健康功能食品、药品或药学组合物及化妆品进行详细说明。
本发明的健康功能饮料含有所述解酒组合物。
本发明的健康功能巧克力含有所述解酒组合物。
在本发明中,“健康功能食品”指的是含有一种以上营养素的天然产品或加工产品。优选地,其为通过使用物理、生化或生物工程技术等对食品赋予附加价值使得该食品为特定目的发挥作用及表现功能的食品组,或者是通过设计和加工使得食品组分所具有的与活体防御节律调节、疾病预防及恢复等相关的活体调节功能对活体充分表达的食品。健康功能食品中包括食品可接受的食品辅助添加剂,更可以包括在健康功能食品的制备中普遍使用的合适的载体、赋形剂和稀释剂。
可以添加本发明有效成分的健康功能食品例如有各种食品、饮料、口香糖、茶和复合维生素等。进一步,还包括特殊营养食品(例如配方奶粉、婴幼儿食品等)、健康补品、糖果(例如零食)、乳制品(例如发酵乳、奶酪等)、其他加工食品、饮料(例如水果、蔬菜饮料、豆浆、发酵饮料等)等,但并不限于此。上述食品、饮料或食品添加剂可由常规制备方法制备。
本发明的健康功能食品包括各种营养素、维生素、矿物质(电解质)、合成调味剂和天然调味剂等调味剂、着色剂、增味剂(奶酪、巧克力等)、果胶酸及其盐、藻酸及其盐、有机酸、保护性胶体增稠剂、pH调节剂、稳定剂、防腐剂、甘油、水、碳酸饮料中使用的碳酸化剂等。这些成分可以单独使用或组合使用。
如此,本发明的健康功能食品如上所述那样可具有多种剂型,尤其可具有粉末、颗粒、片剂、胶囊及饮料等中的任一种剂型,但并不限于此。
本发明的药品或药学组合物含有所述解酒组合物。所述药学组合物通过在有效成分中添加常规的药学上可接受的无毒性载体和赋形剂等而制剂化为药剂学领域中常规的制剂。该制剂例如为片剂、丸剂、硬胶囊和软胶囊、液剂、混悬剂、乳化剂、糖浆、颗粒剂或酏剂(elixirs)等的口服制剂;或者向静脉内、皮下、舌下、肌内给药用的灭菌性水性或油状溶剂的肠胃外制剂。
可在本发明药学组合物中使用且在药剂学上可接受的载体为制剂化时通常使用的载体,包括乳糖、右旋糖、蔗糖、山梨醇、甘露醇、淀粉、阿拉伯胶、磷酸钙、藻酸盐、明胶、硅酸钙、微晶纤维素、聚乙烯吡咯烷酮、纤维素、水、糖浆、甲基纤维素、羟基苯甲酸甲酯(Methyl hydroxybenzoate)、羟基苯甲酸丙酯(Propyl hydroxybenzoate)、滑石、硬脂酸镁及/或矿物油等,但并不限于此。
可在本发明的药学组合物中使用的赋形剂包括甜味剂、粘合剂、增溶剂、溶解助剂、润湿剂、乳化剂、等渗剂、吸附剂、崩解剂、抗氧化剂、防腐剂、助悬剂、填充剂和香料等,这种赋形剂的比例及性质可根据所选片剂的溶解度及化学特性、所选给药途径及标准药剂实务决定。赋形剂的示例可以列举乳糖、右旋糖、蔗糖、甘露醇、山梨糖醇、纤维素、甘氨酸、二氧化硅、滑石、硬脂酸、固醇、硬脂酸镁、硅酸镁铝、淀粉、明胶、黄蓍胶、精氨酸、海藻酸钠、甲基纤维素、羧甲基纤维素钠、琼脂、水、乙醇、聚乙二醇、聚乙烯吡咯烷酮、氯化钠、氯化钙、柑橙香精、草莓香精和香草味等。
此外,本发明的药学组合物可剂型化为肠胃外给药形式,这种情况下可采用静脉内给药、腹膜内给药、肌内给药、皮下给药或局部给药等,但不限于此。此时,为了制剂化为肠胃外给药用剂型,所述药学组合物可通过在水中混合有效成分与稳定剂或缓冲剂,从而制备成溶液或悬浮液,并将这种溶液或悬浮液制备成安瓿(Ampule)或小瓶(Vial)的单位给药型。
此外,本发明的药学组合物可被灭菌,或者进一步包括辅助剂,例如防腐剂、稳定剂、可湿性粉剂或乳化促进剂、用于调节渗透压的盐及/或缓冲剂等,也可以进一步包括其他有助于治疗的物质,并可通过混合、颗粒化或涂布等常规方法制剂化。
此外,在本发明的药学组合物中有效成分对包括人的哺乳类的给药使用量可根据患者的年龄、体重、性别、给药形式、健康状态及疾病程度而不同。一般可以以每天0.001~500㎎/㎏(体重),优选以每天0.01~100㎎/㎏(体重)的有效量来包含在所述药学组合物中,这种药学组合物可以被分成一日一次或两次以上的量来通过口服或肠胃外途径给药。然而,给药量可根据给药途径、疾病的严重程度、性别、体重和年龄等而增减,因此所述给药量不以任何方式限定本发明。
本发明的化妆品含有所述解酒组合物。
在本发明中,所述化妆品虽然不受限制,但可以是从由溶液、悬浮液、乳液、糊剂、凝胶、乳霜、乳液、粉末、肥皂、油、粉底、乳液粉底、蜡状粉底和喷雾剂组成的组中选择的任何一种剂型。
所述化妆品除了有效成分以外,可进一步包括化妆品中通常使用的成分,例如可包括抗氧化剂、稳定剂、增溶剂、维生素、颜料及香料等常规的助剂以及载体。
另外,所述化妆品可制备成本领域中通常制备的任何剂型,例如可剂型化为溶液、悬浮液、乳液、糊剂、凝胶、乳霜、乳液、粉末、肥皂、含表面活性剂的清洁剂、油、粉末粉底、乳液粉底、蜡状粉底和喷雾剂等,但并不一定限于此。更为详细地,可制备成弹性乳液、收敛性乳液、滋养乳液、滋养霜、按摩霜、精华液、面膜喷雾剂或粉末等剂型。
当所述化妆品的剂型为糊剂、乳霜或凝胶时,可将动物油、植物油、蜡、石蜡、淀粉、黄蓍胶、纤维素衍生物、聚乙二醇、硅酮、膨润土、二氧化硅、滑石或氧化锌作为载体成分使用。
此外,当本发明的化妆品的剂型为粉末或喷雾剂时,可将乳糖、滑石、二氧化硅、氢氧化铝、硅酸钙或聚酰胺粉作为载体成分使用,尤其在化妆品的剂型为喷雾剂时,可进一步包括氯氟烃、丙烷/丁烷或二甲醚等推进剂。
此外,当本发明的化妆品的剂型为溶液或乳液时,可将溶剂、增溶剂或乳化剂作为载体成分使用,例如可使用水、乙醇、异丙醇、碳酸乙酯、乙酸乙酯、苯甲醇、苯甲酸苄酯、丙二醇、1,3-丁二醇油、甘油脂族酯、聚乙二醇或山梨聚糖的脂肪酸酯。
此外,当本发明的化妆品的剂型为悬浮液时,可将液态稀释剂,例如水、乙醇或丙二醇;悬浮剂,例如乙氧基异硬脂醇、聚氧乙烯山梨醇酯和聚氧乙烯山梨糖酯;微晶纤维素、甲基氢氧化铝、膨润土、琼脂或黄蓍胶等作为载体成分使用。
下面,通过实施例更加具体说明本发明的内容。实施例是为了更加具体说明本发明而提供的,本发明的权利范围不受其限制。
[实验材料、试剂和设备]
-枳椇子、葛根、葛花、丹参、甘草、灵芝、蜂蜜和白糖等从传统市场购买使用。
-氧化锌、果糖、维生素B1等试剂和材料从西格玛-默克(Sigma,Merck)购买使用。
-其他测量设备在韩国购买使用。
[实施例1]制备解酒组合物
清洗枳椇子(3.5kg)、葛根(0.8kg)、葛花(0.7kg)、丹参(0.5kg)、甘草(0.1kg)和灵芝(0.1kg)后添加纯净水150L,在100℃下萃取四小时后采用真空浓缩机进行减压浓缩,获得12.6g的粉末萃取物。
之后,将所述粉末4.2g和氧化锌(1500g)、蜂蜜(100g)、白糖(50g)和果糖(200g)溶解于纯净水10L中,获得100次用量。
将所获得的混合液过滤,并通过高温瞬间灭菌器,在95℃中灭菌30秒。另行过滤维生素B1(150g)进行灭菌处理。将这些物质填充在容器中后,封装制备解酒组合物。
[试验例1]解酒评价
针对随机选定的20来岁健康男女18名,让他们摄取一般饮用的酒精浓度18%的烧酒180ml,经过30分钟后,让他们摄取在实施例1中制备的解酒组合物120ml。
从摄取后经过30分钟的时间点开始测量呼气酒精浓度四小时。
在图1及图2中示出其结果。
从所述结果可知,本发明的解酒饮料在饮酒后两个小时后开始几乎都分解了酒精成分,表现出宿醉现象完全恢复到几乎未能检测酒精成分的卓越的效果。尤其与服用肯迪醒的情况相比,在服用本发明的组合物的情况下,酒精浓度的消失速度快两倍以上,可知本发明的组合物具有优异的解酒效果。
在结束所述四小时的试验后,让实验组在第二天上午六点起床,测量夜间解酒情况。
结果,与所述摄取后经过四小时相比,大部分实验组表现出缓解了一般宿醉相关症状即头痛、困倦、注意力不集中、记忆力减退和食欲不振等症状,消除了宿醉,从而确认到总体上改善了宿醉。尤其对头晕、恶心、腹痛、腹泻及神经过敏症状,与空白试验组及对照组相比得到明显优异的恢复效果,重新确认到对消化系统的稳定表现出更加显著的效果。
[剂型例1]制备成饮料剂型
将所述实施例1中制备的解酒组合物80mg、维生素E 9mg、维生素C 9mg、柠檬酸0.6g及液态低聚糖25g混合之后,添加纯净水300mL,每个瓶中填充200mL之后,在130℃中灭菌三秒,以制备解酒饮料。
[剂型例2]制备成巧克力剂型
采用所述实施例1中制备的解酒组合物5g、白糖34.5g、可可脂34g、可可块15g、可可粉15g、卵磷脂0.5g和香草味0.5g,用常规方法制备解酒巧克力。
Claims (18)
2.根据权利要求1所述的解酒组合物的制备方法,其中,
所述第一混合物相对于所述枳椇子100重量份,包含1~50重量份的葛根、1~50重量份的葛花及1~10重量份的甘草。
3.根据权利要求1所述的解酒组合物的制备方法,其中,
所述溶剂萃取时的溶剂为水或碳原子数为(C1-C4)的低元醇。
4.根据权利要求3所述的解酒组合物的制备方法,其中,
在所述溶剂萃取时,在70~200℃中萃取1~20小时。
5.根据权利要求1所述的解酒组合物的制备方法,其中,
所述第二混合物相对于所述干粉1重量份,包含100~500重量份的氧化锌及10~100重量份的所述糖化合物。
6.根据权利要求1所述的解酒组合物的制备方法,其中,
所述R1至R5及R7至R10分别独立地为氢或(C1-C3)烷基;
所述R6为氢、羟基、羟基(C1-C3)烷基或(C1-C3)烷氧基。
7.根据权利要求1所述的解酒组合物的制备方法,其中,
所述R1至R5及R7至R10为氢,
所述R6为氢、羟基或-(CH)2-OH。
8.根据权利要求1所述的解酒组合物的制备方法,其中,
具有所述化学式1或化学式2的结构的化合物为葡萄糖、果糖或半乳糖。
9.根据权利要求1所述的解酒组合物的制备方法,其中,
所述第一混合物进一步包括丹参、灵芝或其混合物。
10.根据权利要求1所述的解酒组合物的制备方法,其中,
所述第二混合物进一步包括维生素B1。
11.根据权利要求10所述的解酒组合物的制备方法,其中,
所述第二混合物及所述维生素B1在分别灭菌后混合。
13.根据权利要求12所述的解酒组合物,其中,
所述R1至R5及R7至R10分别独立地为氢或(C1-C3)烷基;
所述R6为氢、羟基、羟基(C1-C3)烷基或(C1-C3)烷氧基。
14.根据权利要求12所述的解酒组合物,其中,
所述R1至R5及R7至R10为氢,
所述R6为氢、羟基或-(CH)2-OH。
15.一种健康功能饮料,含有权利要求12至14中的任一项所述的解酒组合物。
16.一种健康功能巧克力,含有权利要求12至14中的任一项所述的解酒组合物。
17.一种药品,含有权利要求12至14中的任一项所述的解酒组合物。
18.一种化妆品,含有权利要求12至14中的任一项所述的解酒组合物。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2019-0013952 | 2019-02-01 | ||
KR20190013952 | 2019-02-01 | ||
KR1020200009599A KR20200096139A (ko) | 2019-02-01 | 2020-01-28 | 숙취 해소용 조성물 및 그 제조방법 |
KR10-2020-0009599 | 2020-01-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111514197A true CN111514197A (zh) | 2020-08-11 |
Family
ID=71900902
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010078461.6A Withdrawn CN111514197A (zh) | 2019-02-01 | 2020-02-03 | 解酒组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111514197A (zh) |
-
2020
- 2020-02-03 CN CN202010078461.6A patent/CN111514197A/zh not_active Withdrawn
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101383146B1 (ko) | 복합생약 추출물을 함유하는 숙취해소 및 간질환의 치료 및 예방용 조성물 | |
RU2294208C2 (ru) | Применение экстракта обработанного женьшеня и выделенных из него сапонинов | |
KR101498780B1 (ko) | 숙취의 예방 또는 치료용 조성물 | |
EP2436388B1 (en) | Composition for increasing the bioavailability of saponin | |
US7371416B2 (en) | Method for preparing processed ginseng to obtain increased amount of ginsenoside RG5 | |
US11207367B2 (en) | Composition for preventing or alleviating hangover, containing Longan arillus extract | |
JP2003192605A (ja) | リパーゼ阻害剤 | |
WO2019132625A1 (ko) | 약초 혼합추출물을 유효성분으로 함유하는 아토피 피부염의 예방, 개선 또는 치료용 조성물 | |
WO2016099043A1 (ko) | 숙취해소용 및 간기능 개선용 음료 조성물 | |
KR20150057333A (ko) | 구상나무 추출물을 포함하는 비만 예방 또는 개선용 조성물 | |
KR20170027914A (ko) | 황칠 추출물 또는 황칠액 발효대사체를 포함하는 통풍 예방 또는 치료용 조성물 | |
KR20160081205A (ko) | 산수국 추출물을 포함하는 비만 예방 또는 개선용 조성물 | |
CN106581115B (zh) | 含芫根和人参的组合物及其应用 | |
CN112167635A (zh) | 一种解酒护肝缓释微胶囊及其制备方法 | |
KR100638491B1 (ko) | 숙취해소용 조성물 및 이를 유효성분으로 함유하는숙취해소제 | |
KR20140137289A (ko) | 포공영 추출물을 함유하는 숙취해소 및 간 질환의 치료 및 예방용 조성물 | |
KR101365794B1 (ko) | 숙취해소 및 간 보호기능 개선 조성물 | |
KR101821925B1 (ko) | 지실 및 육계의 복합 추출물을 포함하는 알레르기성 피부염 예방 또는 치료용 조성물 | |
KR20200096139A (ko) | 숙취 해소용 조성물 및 그 제조방법 | |
KR100527109B1 (ko) | 부추 추출물을 함유하는 통풍의 예방 및 치료용 약학조성물 | |
KR101100278B1 (ko) | 생약재 발효 추출물의 제조 방법 및 이로부터 제조된 추출물을 유효성분으로 포함하는 신경퇴행성 질환의 예방 또는 치료용 조성물 | |
CN111514197A (zh) | 解酒组合物及其制备方法 | |
KR20140080289A (ko) | 산화적 뇌손상 및 뇌기능 장애의 예방 또는 치료용 조성물 및 이의 제조방법 | |
KR100527105B1 (ko) | 부추 추출물을 함유하는 통풍의 예방 및 치료용 약학조성물 | |
KR101738206B1 (ko) | 지실 및 육계의 복합 추출물을 포함하는 알레르기성 피부염 예방 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20200811 |